Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial

• Published in: Clinical infectious diseases 2017-02, Vol.64 (4), p.451-458
• Main Authors: Sayasone, Somphou, Meister, Isabel, Andrews, Jason R., Odermatt, Peter, Vonghachack, Youthanavanh, Xayavong, Syda, Senggnam, Kanpaseuth, Phongluxa, Khampheng, Hattendorf, Jan, Bogoch, Isaac I., Keiser, Jennifer
• Format: Article
• Language: English
• Subjects: Adult; Animals; Anthelmintics - administration & dosage; Anthelmintics - adverse effects; ARTICLES AND COMMENTARIES; Clinical trials; Coinfection; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nematodes; Opisthorchiasis - drug therapy; Opisthorchiasis - parasitology; Opisthorchis; Opisthorchis viverrini; Parasite Egg Count; Parasite Load; Parasites; Praziquantel - administration & dosage; Praziquantel - adverse effects; Prescription drugs; Risk factors; Safety; Treatment Outcome; Trematoda
• ISSN: 1058-4838; 1537-6591
• DOI: 10.1093/cid/ciw785

Background. The liver fluke Opisthorchis viverrini, highly prevalent in Southeast Asia, is an important public health burden, including a risk factor for developing an aggressive bile duct cancer, cholangiocarcinoma, in chronically infected patients. Praziquantel, administered at a single 40 mg/kg dose in preventive chemotherapy programs and 3 × 25 mg/kg for individual treatment, is the drug of choice, yet information on the nature of the dose-response relationship is lacking. Methods. We performed a randomized, parallel, single-blind dose-ranging phase 2 trial in the Lao People's Democratic Republic in O. viverrini–infected adults. Patients were randomly assigned to 30 mg/kg, 40 mg/kg, 50 mg/kg, or 3 × 25 mg/kg praziquantel or placebo. Adverse events were recorded at baseline, 3 hours, and 24 hours posttreatment. Cure rates (CRs) and egg reduction rates (ERRs) were estimated 3 weeks after drug administration using available case analysis. Dose-response curves were predicted using Emax models. Results. Two-hundred seventeen O. viverrini–infected patients were assigned to the 5 treatment arms. The majority (94.3%) of patients harbored light infections. The Emax model predicted a high efficacy among the observed dose range. We observed CRs ranging from 92.7% to 95.5% and ERRs >99.5% for all praziquantel treatment groups. Adverse events were mild but higher in the standard treatment group (3 × 25 mg/kg) than in the single-dose treatment arms. Conclusions. Single-dose praziquantel appears to be as efficacious as the standard 3 × 25 mg/kg regimen for the treatment of O. viverrini infectins, while presenting fewer adverse events. Further studies are necessary in moderate and heavy O. viverrini infections. Clinical Trials Registration. Randomized Controlled Trials (ISRCTN77186750).